ArticleProceedings of the National Academy of Sciences of the United States of America2026
Large declines in organofluorine contamination indicated by subarctic marine mammal tissues.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Bioaccumulation dynamics of perfluorooctane sulfonic acid (PFOS) and a binary mixture of PFOS and perfluorohexane sulfonic acid (PFHxS) in northern bobwhite (Colinus virginianus): a mini review.Ecotoxicology (London, England) · 2026Review
- PFAS-defined liquid crystal monomers: An overlooked class of organofluorine contaminants.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Reply to Li et al.: Fluorinated liquid crystal monomers highlight a need for more data on emerging PFAS.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- The Role of ES&T in Advancing Environmental Toxicology and Chemical Risk Assessment: Past, Present, and Future.Environmental science & technology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
The ocean is thought to be the terminal sink for per- and polyfluoroalkyl substances (PFAS), persistent organofluorine chemicals used widely in modern commerce for decades. Industry and stewardship programs phased out the most abundantly produced legacy PFAS in the early 2000s due to toxicity concerns. However, they have since been replaced by shorter carbon chain and "novel" chemistries, and past work hypothesized likely increases in these replacement PFAS that were not previously quantifiable. To address this gap, we measured bulk extractable organofluorine (EOF) in archived liver and muscle tissues from pelagic Subarctic pilot whales over the last several decades. Results show EOF concentrations peaked in 2011 and declined by over 60% by 2023. Among a broad suite of targeted and suspect PFAS measured using high-resolution mass spectrometry, only one was consistently increasing through 2023. Tissue concentrations of four main legacy PFAS that accounted for over 75% of EOF were all decreasing by 2023. The timing of peak concentrations depended primarily on whether they were transported to the subarctic by ocean circulation or atmospheric deposition, with the latter declining much faster. Oceanic transport and bioaccumulation modeling suggests that decadal-scale lags between production and food web bioaccumulation are primarily driven by marine transport processes. Large declines in tissue concentrations in this study reinforce the effectiveness of phase-outs in chemical production. However, other work showing stable or increasing EOF in human serum suggests many emerging PFAS with more neutral physicochemical properties may be preferentially accumulating in terrestrial and nearshore environments compared to legacy PFAS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.